Cliff Asness’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$702M Sell
1,126,080
-104,928
-9% -$71.4M 0.24% 75
2026
Q1
$946M Buy
1,231,008
+235,298
+24% +$180M 0.43% 29
2025
Q4
$769M Buy
995,710
+274,356
+38% +$186M 0.4% 37
2025
Q3
$406M Buy
721,354
+606,612
+529% +$343M 0.26% 72
2025
Q2
$59.7M Sell
114,742
-121,208
-51% -$67.7M 0.05% 489
2025
Q1
$149M Buy
235,950
+28,865
+14% +$19.9M 0.15% 173
2024
Q4
$147M Sell
207,085
-18,449
-8% -$15.5M 0.19% 133
2024
Q3
$235M Buy
225,534
+36,243
+19% +$40.3M 0.32% 54
2024
Q2
$199M Buy
189,291
+6,839
+4% +$6.63M 0.3% 65
2024
Q1
$175M Sell
182,452
-13,429
-7% -$12.8M 0.3% 75
2023
Q4
$172M Buy
195,881
+5,712
+3% +$4.7M 0.32% 65
2023
Q3
$157M Sell
190,169
-29,481
-13% -$23.2M 0.32% 63
2023
Q2
$155M Sell
219,650
-21,124
-9% -$16.3M 0.33% 64
2023
Q1
$198M Sell
240,774
-68,381
-22% -$51.6M 0.43% 38
2022
Q4
$221M Sell
309,155
-121,146
-28% -$89.4M 0.5% 31
2022
Q3
$296M Sell
430,301
-120,115
-22% -$75.6M 0.72% 18
2022
Q2
$323M Buy
550,416
+41,635
+8% +$27.1M 0.73% 15
2022
Q1
$355M Buy
508,781
+59,162
+13% +$37.4M 0.67% 14
2021
Q4
$284M Buy
449,619
+173,586
+63% +$107M 0.51% 31
2021
Q3
$167M Buy
276,033
+81,918
+42% +$50.9M 0.31% 68
2021
Q2
$106M Sell
194,115
-96,546
-33% -$48.9M 0.18% 130
2021
Q1
$138M Sell
290,661
-63,244
-18% -$30.8M 0.22% 108
2020
Q4
$167M Sell
353,905
-111,199
-24% -$60M 0.3% 74
2020
Q3
$260M Buy
465,104
+103,282
+29% +$62.6M 0.44% 43
2020
Q2
$223M Sell
361,822
-23,706
-6% -$13.5M 0.36% 58
2020
Q1
$179M Buy
385,528
+42,468
+12% +$17.5M 0.3% 76
2019
Q4
$129M Buy
343,060
+48,009
+16% +$16.2M 0.15% 178
2019
Q3
$81.2M Sell
295,051
-55,846
-16% -$16.5M 0.1% 258
2019
Q2
$110M Sell
350,897
-32,960
-9% -$11M 0.12% 205
2019
Q1
$157M Buy
383,857
+152,469
+66% +$62.8M 0.17% 165
2018
Q4
$86.4M Buy
231,388
+47,207
+26% +$17.3M 0.1% 223
2018
Q3
$74.4M Buy
184,181
+71,623
+64% +$27.3M 0.07% 290
2018
Q2
$38.8M Sell
112,558
-178,740
-61% -$55.9M 0.04% 463
2018
Q1
$100M Buy
291,298
+197,650
+211% +$68.7M 0.11% 227
2017
Q4
$35.2M Buy
93,648
+45,447
+94% +$18.4M 0.04% 476
2017
Q3
$21.6M Buy
48,201
+42,577
+757% +$20.3M 0.03% 573
2017
Q2
$2.76M Sell
5,624
-3,181
-36% -$1.39M ﹤0.01% 1258
2017
Q1
$3.41M Buy
8,805
+5,884
+201% +$2.18M ﹤0.01% 1168
2016
Q4
$1.07M Sell
2,921
-531
-15% -$202K ﹤0.01% 1671
2016
Q3
$1.39M Buy
3,452
+1,167
+51% +$468K ﹤0.01% 1586
2016
Q2
$798K Sell
2,285
-8,806
-79% -$3.39M ﹤0.01% 1694
2016
Q1
$4M Sell
11,091
-34,259
-76% -$14.1M 0.01% 952
2015
Q4
$24.6M Buy
45,350
+24,164
+114% +$13.1M 0.04% 499
2015
Q3
$9.85M Buy
21,186
+4,382
+26% +$2.35M 0.02% 631
2015
Q2
$8.57M Buy
16,804
+3,157
+23% +$1.54M 0.02% 661
2015
Q1
$6.16M Buy
13,647
+4,974
+57% +$2.11M 0.01% 712
2014
Q4
$3.56M Buy
8,673
+2,734
+46% +$1.08M 0.01% 1032
2014
Q3
$2.14M Sell
5,939
-11,100
-65% -$3.72M 0.01% 1225
2014
Q2
$4.81M Sell
17,039
-15,000
-47% -$4.45M 0.01% 916
2014
Q1
$9.62M Sell
32,039
-2,600
-8% -$801K 0.03% 607
2013
Q4
$9.53M Sell
34,639
-8,077
-19% -$2.32M 0.03% 617
2013
Q3
$13.4M Buy
42,716
+11,305
+36% +$2.97M 0.05% 464
2013
Q2
$7.06M Buy
+31,411
New +$7.31M 0.03% 715

Other funds holding REGN

Cliff Asness's REGN Position: Q2 2026 in Review

Cliff Asness reduced its Regeneron Pharmaceuticals (REGN) stake by 8.5% in Q2 2026, selling an estimated $71.4M and leaving 1,126,080 shares worth $702M. The position accounts for 0.24% of the portfolio, ranked #75.

Cliff Asness first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $946M in Q1 2026. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cliff Asness held 1,126,080 shares of Regeneron Pharmaceuticals worth $702M as of Q2 2026.
  • Cliff Asness sold 104,928 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $71.4M.
  • Regeneron Pharmaceuticals made up 0.24% of Cliff Asness's portfolio in Q2 2026, its #75 holding.
  • Cliff Asness first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Cliff Asness's Regeneron Pharmaceuticals position peaked at $946M in Q1 2026.
  • 1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.